Bevacizumab is medication used to treat colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma and age-related macular degeneration.
It is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A).
It is administered through intraveous injection every 3 weeks.
In 2016, it sold €1.2 million in Europe.
Labs that test for drug level: